Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
ConclusionRoxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4 months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies.
ConclusionThe CYP2C19 IMs, PMs, and the number of targeted vessels are essential factors associated with MACE risk in dual clopidogrel-treated Uygur population with ACS following PCI. These data provide valuable insights into the genetic polymorphisms affecting clopidogrel response among minority groups in China.
ConclusionThe majority of patient-reported ADRs were non-serious. However, a relevant number of non-labelled even serious ADRs was reported for novel compounds by patients. Despite well-known limitations of patient-reported ADRs, this web-based ADR reporting system contributes to the identification of new ADRs and thus can help to improve patients ’ safety complementing other pharmacovigilance instruments.
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI, stroke, or hospitalization in the ACTIV-4B trial.Medscape Medical News
Hypertension risk was significantly higher 10 years after preterm delivery and remained elevated up to 43 years, a study shows.Medscape Medical News
Conditions: Hyperkalemia; Chronic Kidney Disease Requiring Chronic Dialysis Interventions: Diagnostic Test: Kalemic Response to Orange Juice; Dietary Supplement: Kalemic Response to Orange Juice with Fiber Sponsors: University of Nevada, Reno; United States Department of Agriculture (USDA); Sierra Nevada Nephrology Consultants, Inc. Enrolling by invitation
Condition: Migraine Headache Interventions: Dietary Supplement: Nutritional Ketogenic Supplement; Dietary Supplement: Isocaloric placebo supplement Sponsors: Nestlé; Healint Pte Ltd; Diex Research Sherbrooke Inc. Recruiting
Conditions: Anemia, Iron Deficiency; Hyperphosphatemia; Renal Insufficiency, Chronic; Renal Anemia; Disease Progression; Cardiovascular; Iron Interventions: Drug: Ferric Citrate 1 GM Oral Tablet [AURYXIA]; Drug: Placebo Sponsors: USRC Kidney Research; Akebia Therapeutics Not yet recruiting
HIGH blood pressure is widely referred to as the "silent killer" because it wreaks havoc on the cardiovascular system, with great discretion. Symptoms may only arise once the condition has become critical. One mineral deficiency, which is common in the UK, could be increasing your risk of hypertension.
Although cardiovascular disease includes common and possibly life-threatening disorders, such as peripheral artery disease (PAD), venous thromboembolism (VTE), aortic aneurysm, cerebrovascular disease, and others, peripheral vascular diseases are often underdiagnosed and undertreated. Individuals with polyvascular disease (ie, atherosclerosis in multiple arterial beds) are at higher risk of major adverse events and mortality than patients with coronary artery disease or peripheral vascular disease alone.